公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.